Moosi Depression Presentation
Moosi Depression Presentation
Moosi Depression Presentation
Management And
Prevention Of
DepressionPresented By,
Syed Mohammad Moosi Raza Ali
Khan
Roll No: 88
Guidance, Support and Inputs:
Dr Deeksha Elwadhi (Dept. of Psychiatry)
Dr Rashmi Agarwala (Dept. of Community Med.)
Fatima Bv (MBBS 2014)
PHARMACOLOGICAL
TREATMENT:
ANTIDEPRESSANTS
NDRIs : Imipramine,
Bupropion Clomipramine
Tricyclic
Antidepressa Paroxetine,
Atomoxetine, nts Dapoxetine
Reboxetine
SARIs :
Phenylpipera SNRIs
zine
MAO-A
Mianserin, Inhibitors:
Mirtazapin Moclobemide
Basic Pathology
&
Antidepressants:
How They Act
• Safety
STEPS to selection
-Therapeutic index
-Drug-drug interactions- Pharmacodynamics,
Pharmacokinetics
• Tolerability
• Efficacy
-Overall
-Unique spectrum of activity
-Rate of response
-Maintenance and prophylaxis
• Payment
• Simplicity - Ease of administration
[ Preskorn SH, J Clin Psychiatry, 1994]
Non-
Pharmacological
Treatment
Electroconvulsive Therapy
Modulation of monoamines
Definition:
Electricity applied
transcranially via
electrode placed Change in neurotrophic
on the scalp to Mechanism
factors
induce seizure of action
under surgical
anesthesia Anticonvulsant factors
Neurophysiological factors
INDICATIONS:
‽Severe depressive illness (with suicidal
symptoms)
‽Psychotic Depression as in prolonged or
severe mania
‽Resistant to Anti-depressant drug treatment
‽Refuses to eat dangerous malnutrition.
‽Accompanied by psychotic symptoms,
catatonia symptoms
CONTRAINDICATIONS
No absolute contraindication to ECT, however it is best
avoided in the following conditions
PSYCHOTHERA
PY Behavioral & Cognitive
Behavioral Therapy
Concentrate on defining how a
person’s behavior affect
problems that contribute to
depression.
Seconda
ry
Primary
Primary Prevention
· Reduce individual vulnerability
Early intervention
Tertiary Prevention
Reduce relapse and recurrence